Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 1.00 |
| ▸ | TK2 | O00142 | 8/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720003 | 0.91 | TYMP (0.82) | TYMPTK2TK1 | |
| SCHEMBL8713764 | 0.81 | TYMP (0.67) | TYMPMAPK1HPGD | |
| SCHEMBL6153435 | 0.80 | TYMP (0.66) | TYMPTK2MAPK1HPGDTK1 | |
| SCHEMBL16037866 | 0.80 | TYMP (0.65) | TYMPTK2MAPK1TK1 | |
| SCHEMBL19181390 | 0.78 | TYMP (0.63) | TYMPTK2HPGDTK1 | |
| SCHEMBL17583277 | 0.77 | TYMP (0.63) | TYMPTK2MAPK1HPGDTK1 | |
| SCHEMBL8780707 | 0.76 | TYMP (0.61) | TYMPTK2MAPK1HPGDTK1 | |
| SCHEMBL20586239 | 0.76 | TYMP (0.61) | TYMPTK2MAPK1TK1 | |
| SCHEMBL19929317 | 0.76 | TYMP (0.60) | TYMPTK2MAPK1HPGDTK1 | |
| SCHEMBL30903369 | 0.75 | TYMP (0.60) | TYMPTK2MAPK1HPGDTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144896-A1 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | SIREN BIOTECHNOLOGY, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4598543-A2 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | Siren Biotechnology, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| CN-120158382-A | Rhodosporidium toruloides strain with high homologous recombination efficiency and construction method and application thereof | 中国科学院大连化学物理研究所 | 2025-06-17 | — | — | CN | claimed |
| CN-119150816-B | Free text-based common sense knowledge editing method and device and electronic equipment | 北京智源人工智能研究院 | 2025-03-07 | — | — | CN | claimed |
| CN-119150816-A | Free text-based common sense knowledge editing method and device and electronic equipment | 北京智源人工智能研究院 | 2024-12-17 | — | — | CN | claimed |
| US-20240345289-A1 | OCEAN-ONTO-LAND DROUGHT (OTLD) IDENTIFICATION AND PROPAGATION MECHANISM ANALYSIS METHOD AND SYSTEM | CHINA UNIVERSITY OF GEOSCIENCES (WUHAN) (CN) | 2024-10-17 | — | — | US | claimed |
| CN-111581861-B | Continuous damage prediction method and system for high-temperature oxidation corrosion of high-chromium steel member | 华南理工大学 | 2024-05-28 | — | — | CN | claimed |
| WO-2024077089-A2 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | SIREN BIOTECHNOLOGY, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | UNIV INDIANA TRUSTEES (US) | 2024-03-14 | — | — | US | claimed |
| CN-111632153-B | Chemical gene drug co-loaded targeting nano drug delivery system and preparation method thereof | 宁夏医科大学 | 2023-02-24 | — | — | CN | claimed |
| EP-3059645-B1 | METHOD AND COMPUTER PROGRAM PRODUCT FOR CONTROLLING ANAEROBIC CODIGESTERS | UNIV SANTIAGO COMPOSTELA (ES) | 2022-06-01 | — | — | EP | claimed |
| US-11342522-B2 | White-light QLED component, backlight module and illumination apparatus | NATIONAL TSING HUA UNIVERSITY (TW) | 2022-05-24 | — | — | US | claimed |
| CN-109939241-B | Double-prodrug co-assembled nano-targeting drug delivery system and preparation method thereof | 宁夏医科大学 | 2022-02-15 | — | — | CN | claimed |
| US-20260144896-A1 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | SIREN BIOTECHNOLOGY, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | disclosed |
| US-20260139239-A1 | VARIANTS OF TEV PROTEASE AND USES THEREOF | NUMAFERM GMBH (DE) | 2026-05-21 | — | — | US | disclosed |
| WO-2006114065-A2 | USE OF COMPOUNDS TO INHIBIT NEOPLASIA | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY A CADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139239-A1 | VARIANTS OF TEV PROTEASE AND USES THEREOF | CTRL, MME, MMEL1 | TYMP 1592/4885TK2 3979/4885MAPK1 3659/4885 |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | BRAF, TTK, CKS1B | TYMP 1123/4885TK2 2619/4885MAPK1 824/4885 |
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | DDAH1, ADM2, NPPA | TYMP 582/4885TK2 1445/4885MAPK1 3910/4885 |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | TYMP 894/4885TK2 2304/4885MAPK1 815/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | TYMP 46/4885TK2 222/4885MAPK1 2372/4885 |
| US-20260144896-A1 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | DNMT3L, TRMT1L, SPPL2A | TYMP 399/4885TK2 2165/4885MAPK1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.